Work

Not just g RAS ping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Year: 2014

Type: review

Abstract: Mutations in Kirsten rat-sarcoma (KRAS) are well appreciated to be major drivers of human cancers through dysregulation of multiple growth and survival pathways. Similar to many other non-kinase oncogenes and tumor suppressors, efforts to directly target KRAS pharmaceutically have not yet materialized. As a result, there is broad interest in an alternative approach to develop therapies that induce synthetic lethality in cancers with mutant KRAS, therefore exposing the particular vulnerabilities of these cancers. Fueling these efforts is our increased understanding into the biology driving KRAS mutant cancers, in particular the important pathways that mutant KRAS governs to promote survival. In this mini-review, we summarize the latest approaches to treat KRAS mutant cancers and the rationale behind them.

Source: Cancer Science

DOI: 10.1111/cas.12383

Authors: Hiromichi Ebi, Anthony C. Faber, Jeffrey A. Engelman, Seiji Yano

Institutions: Kanazawa University, Cancer Research Institute of Kanazawa University, Harvard University, Massachusetts General Hospital

Language: English

Topic: Protein Kinase Regulation and GTPase Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,600